Notice to Shareholders - AGM Virtual Access

RNS Number : 4149R

e-Therapeutics plc

06 July 2022

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Notice to Shareholders - Annual General Meeting Virtual Access

London, UK, 6 July 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces it is offering shareholders the opportunity to attend the forthcoming AGM virtually via a conference call facility.

Shareholders that wish to join the AGM conference call, are requested to contact [e-mail] for dial-in details.  

The AGM will be held at 12:30p.m. on 19 July 2022 at 4 Kingdom Street, Paddington, London, W2 6BD.

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO  James Chandler, VP IR & Strategic Communications	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

 

About e-therapeutics plc

e-therapeutics plc is a UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

 

END

 

 

NOAUVUVRUOUBRAR